Is Uber Stock a Buy on the Dip?
Shares of Uber Technologies (NYSE:UBER) have been fading fast in…
Sell
38
WVE Quote, Financials, Valuation and Earnings
Last price:
$12.92
Seasonality move
:
-4.34%
Day range:
$12.87 - $13.54
52-week range:
$3.50 - $16.74
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
31.57x
P/B ratio:
14.52x
Volume:
420.4K
Avg. volume:
1.1M
1-year change:
153.44%
Market cap:
$2.1B
Revenue:
$113.3M
EPS (TTM):
-$1.11
Analysts' Opinion
-
Consensus RatingWAVE Life Sciences has received a consensus rating of Buy. The company's average rating is a Buy based on 7 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $22.30, WAVE Life Sciences has an estimated upside of 65.43% from its current price of $12.90.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $15.00 representing 100% downside risk from its current price of $12.90.
Fair Value
-
According to the consensus of 8 analysts, WAVE Life Sciences has 65.43% upside to fair value with a price target of $22.30 per share.
WVE vs. S&P 500
-
Over the past 5 trading days, WAVE Life Sciences has overperformed the S&P 500 by 1.16% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
WAVE Life Sciences does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
WAVE Life Sciences revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter WAVE Life Sciences reported revenues of -$7.7M.
Earnings Growth
-
WAVE Life Sciences has grown year-over-year earnings for 0 quarters straight. In the most recent quarter WAVE Life Sciences reported earnings per share of -$0.47.
Enterprise value:
1.7B
EV / Invested capital:
12.32x
Price / LTM sales:
31.57x
EV / EBIT:
--
EV / Revenue:
32.55x
PEG ratio (5yr expected):
-0.44x
EV / Free cash flow:
-12.30x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-55.78%
Net Income Margin (TTM):
-265.84%
Return On Equity:
-437.99%
Return On Invested Capital:
-437.99%
Operating Margin:
-177.72%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $4.2M | $85.5M | $53.6M | $49.2M | -$7.7M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$155.3M | -$92.9M | -$152.1M | $4.4M | -$63.9M | |
| EBITDA | -$145.1M | -$83.4M | -$143.4M | $6.7M | -$61.8M | |
| Diluted EPS | -$2.27 | -$0.87 | -$1.11 | $0.07 | -$0.47 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $258.4M | $158M | $131.4M | $158.6M | $324.5M | |
| Total Assets | $310.1M | $200.5M | $181.5M | $199.9M | $358.5M | |
| Current Liabilities | $109.7M | $31.6M | $64.3M | $100M | $170.7M | |
| Total Liabilities | $201.8M | $170.6M | $186M | $240.4M | $216.9M | |
| Total Equity | $108.2M | $29.9M | -$4.5M | -$40.5M | $141.6M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$101.4M | -$19.6M | -$140.6M | -$34.5M | -$46.5M | |
| Cash From Investing | -$26.1M | $24.1M | -$1.2M | -$198K | -$383K | |
| Cash From Financing | $100.9M | $38.6M | $312.9M | $1.7M | $203.7M | |
| Free Cash Flow | -$102.5M | -$20.6M | -$141.8M | -$34.7M | -$46.9M | |
WVE
Sector
Market Cap
$2.1B
$46.5M
Price % of 52-Week High
80.55%
47.23%
Dividend Yield
0%
0%
Shareholder Yield
-24.39%
-0.6%
1-Year Price Total Return
169.06%
-31.38%
Beta (5-Year)
-1.210
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$13.39
200-day SMA
Buy
Level
$8.19
Bollinger Bands (100)
Buy
Level
6.49 - 14.67
Chaikin Money Flow
Sell
Level
-13M
20-day SMA
Sell
Level
$14.10
Relative Strength Index (RSI14)
Sell
Level
42.28
ADX Line
Buy
Level
22.59
Williams %R
Neutral
Level
-77.7778
50-day SMA
Sell
Level
$14.44
MACD (12, 26)
Sell
Level
-0.26
25-day Aroon Oscillator
Sell
Level
-48
On Balance Volume
Neutral
Level
19M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-3.8745)
Sell
CA Score
(Annual)
Level (-4.0644)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (5.1228)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington’s disease.
Stock Forecast FAQ
In the current month, WVE has received 7 Buy ratings 1 Hold ratings, and 0 Sell ratings. The WVE average analyst price target in the past 3 months is $22.30.
-
Where Will WAVE Life Sciences Stock Be In 1 Year?
According to analysts, the consensus estimate is that WAVE Life Sciences share price will rise to $22.30 per share over the next 12 months.
-
What Do Analysts Say About WAVE Life Sciences?
Analysts are divided on their view about WAVE Life Sciences share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that WAVE Life Sciences is a Sell and believe this share price will drop from its current level to $15.00.
-
What Is WAVE Life Sciences's Price Target?
The price target for WAVE Life Sciences over the next 1-year time period is forecast to be $22.30 according to 8 Wall Street analysts, 7 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is WVE A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for WAVE Life Sciences is a Buy. 7 of 8 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of WVE?
You can purchase shares of WAVE Life Sciences via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase WAVE Life Sciences shares.
-
What Is The WAVE Life Sciences Share Price Today?
WAVE Life Sciences was last trading at $12.92 per share. This represents the most recent stock quote for WAVE Life Sciences. Yesterday, WAVE Life Sciences closed at $12.90 per share.
-
How To Buy WAVE Life Sciences Stock Online?
In order to purchase WAVE Life Sciences stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is AMD Stock an All-Time Buy?
Advanced Micro Devices (NASDAQ:AMD) is a high-growth AI stock that…
How High Will Airbnb Stock Go?
Airbnb, Inc. (NASDAQ:ABNB) share price has seen substantial turbulence over…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Buy
54
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Sell
50
LMND alert for Dec 28
Lemonade [LMND] is down 10.69% over the past day.
Buy
60
TSLL alert for Dec 28
Direxion Daily TSLA Bull 2X Shares [TSLL] is down 9.92% over the past day.
Buy
71
SMLR alert for Dec 28
Semler Scientific [SMLR] is down 9.65% over the past day.
